EP Patent

EP0930296A1 — Fluorinated prostaglandin derivatives and medicines

Assigned to Santen Pharmaceutical Co Ltd · Expires 1999-07-21 · 27y expired

What this patent protects

A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: wherein A is a vinylene group, an ethylene group, an ethynylene group or the like, R 1 is …

USPTO Abstract

A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: wherein A is a vinylene group, an ethylene group, an ethynylene group or the like, R 1 is an aryloxyalkyl group, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aralkyl group or the like, R 2 and R 3 are hydrogen atoms, acyl groups or the like, Z is OR 4 , -NHCOR 5 , -NHSO 2 R 6 , -SR 7 , (wherein R 4 , R 5 , R 6 and R 7 are hydrogen atoms, alkyl groups or the like) or the like, and a dual line consisting of solid and broken lines is a single bond, a cis-double bond or a trans-double bond. The medicine is an excellent medicine for an eye disease which has a high pharmacological action and little side effect.

Drugs covered by this patent

Patent Metadata

Patent number
EP0930296A1
Jurisdiction
EP
Classification
Expires
1999-07-21
Drug substance claim
No
Drug product claim
No
Assignee
Santen Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.